Manganese Superoxide Dismutase Acetylation and Dysregulation, Due to Loss of SIRT3 Activity, Promote a Luminal B-Like Breast Carcinogenic-Permissive Phenotype

Antioxidants and Redox Signaling

Volumn 25, Issue 6, 2016, Pages 326-336

  Zou, Xianghui ^a   Santa Maria, Cesar Augusto ^a   O'Brien, Joseph ^a   Gius, David ^a   Zhu, Yueming ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL PROTEIN; REACTIVE OXYGEN METABOLITE; SIRTUIN 3; LYSINE; SUPEROXIDE DISMUTASE; TUMOR MARKER;

ACETYLATION; AGING; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOGENESIS; ENZYME ACTIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HOMEOSTASIS; HORMONAL THERAPY; HUMAN; LONGEVITY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; METASTASIS; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; BREAST NEOPLASMS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; INCIDENCE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RECURRENT DISEASE;

ACETYLATION; AGING; BIOMARKERS, TUMOR; BREAST NEOPLASMS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INCIDENCE; LONGEVITY; LYSINE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PHENOTYPE; RECURRENCE; SIRTUIN 3; SUPEROXIDE DISMUTASE;

EID: 84982281641     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2016.6641     Document Type: Review

References (90)

1. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, Deng CX, and Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A 105: 14447-14452, 2008.
2. Allred DC, Brown P, and Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 6: 240-245, 2004.
3. Barginear MF, Muss H, Kimmick G, Owusu C, Mrozek E, Shahrokni A, Ballman K, and Hurria A. Breast cancer and aging: results of the U13 conference breast cancer panel. Breast Cancer Res Treat 146: 1-6, 2014.
4. Becuwe P, Ennen M, Klotz R, Barbieux C, and Grandemange S. Manganese superoxide dismutase in breast cancer: from molecular mechanisms of gene regulation to biological and clinical significance. Free Radic Biol Med 77: 139-151, 2014.
5. Bell EL, Emerling BM, Ricoult SJ, and Guarente L. SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production. Oncogene 30: 2986-2996, 2011.
6. Bellizzi D, Rose G, Cavalcante P, Covello G, Dato S, De Rango F, Greco V, Maggiolini M, Feraco E, Mari V, Franceschi C, Passarino G, and De Benedictis G. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics 85: 258-263, 2005.
7. Benovic J, Tillman T, Cudd A, and Fridovich I. Electrostatic facilitation of the reaction catalyzed by the manganesecontaining and the iron-containing superoxide dismutases. Arch Biochem Biophys 221: 329-332, 1983.
8. Bidoli E, Fratino L, Bruzzone S, Pappagallo M, De Paoli P, Tirelli U, and Serraino D. Time trends of cancer mortality among elderly in Italy, 1970-2008: an observational study. BMC Cancer 12: 443, 2012.
9. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, and Gius D. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63: 8984-8995, 2003.
10. Brown NS and Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 3: 323-327, 2001.
11. Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, and Carey LA. Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist 20: 474-482, 2015.
12. Chen Y, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S, and Xiong Y. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep 12: 534-541, 2011.
13. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, and Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840, 2009.
14. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics 6: 289-297, 2012.
15. Croxtall JD and McKeage K. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs 71: 363-380, 2011.
16. Dauvois S, White R, and Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106(Pt 4): 1377-1388, 1993.
17. Desouki MM, Doubinskaia I, Gius D, and Abdulkadir SA. Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Hum Pathol 45: 1071-1077, 2014.
18. Dhar SK and St Clair DK. Manganese superoxide dismutase regulation and cancer. Free Radic Biol Med 52: 2209-2222, 2012.
19. Donmez G and Guarente L. Aging and disease: connections to sirtuins. Aging Cell 9: 285-290, 2010.
20. Early Breast Cancer Trialists' Collaborative Group, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, and Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771-784, 2011.
21. Ershler WB and Longo DL. Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 89: 1489-1497, 1997.
22. Ershler WB and Longo DL. The biology of aging: the current research agenda. Cancer 80: 1284-1293, 1997.
23. Fadoukhair Z, Zardavas D, Chad MA, Goulioti T, Aftimos P, and Piccart M. Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. Oncogene 2015. [Epub ahead of print]; DOI: 10.1038/onc .2015.249.
24. Finkel T, Deng CX, and Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 460: 587-591, 2009.
25. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, Teruya-Feldstein J, Moreira PI, Cardoso SM, Clish CB, Pandolfi PP, and Haigis MC. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1a destabilization. Cancer Cell 19: 416-428, 2011.
26. This reference has been deleted.
27. Finley LW and Haigis MC. Metabolic regulation by SIRT3: implications for tumorigenesis. Trends Mol Med 18: 516-523, 2012.
28. Fritz KS, Galligan JJ, Hirschey MD, Verdin E, and Petersen DR. Mitochondrial Acetylome analysis in a mouse model of alcohol-induced liver injury utilizing SIRT3 knockout mice. J Proteome Res 11: 1633-1643, 2012.
29. Gius D, Botero A, Shah S, and Curry HA. Intracellular oxidation/reduction status in the regulation of transcription factors NF-kappaB and AP-1. Toxicol Lett 106: 93-106, 1999.
30. Gius DR, Ezhevsky SA, Becker-Hapak M, Nagahara H, Wei MC, and Dowdy SF. Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. Cancer Res 59: 2577-2580, 1999.
31. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, and Panel M. Strategies for subtypes- dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747, 2011.
32. Guarente L. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 72: 483-488, 2007.
33. Guarente L. Mitochondria-a nexus for aging, calorie restriction, and sirtuins? Cell 132: 171-176, 2008.
34. Guarente L and Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature 408: 255-262, 2000.
35. Haigis MC, Deng CX, Finley LW, Kim HS, and Gius D. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res 72: 2468-2472, 2012.
36. Hallahan DE, Gius D, Kuchibhotla J, Sukhatme V, Kufe DW, and Weichselbaum RR. Radiation signaling mediated by Jun activation following dissociation from a cell type-specific repressor. J Biol Chem 268: 4903-4907, 1993.
37. Hallows WC, Lee S, and Denu JM. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci U S A 103: 10230-10235, 2006.
38. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, Stevens RD, Li Y, Saha AK, Ruderman NB, Bain JR, Newgard CB, Farese RV, Jr., Alt FW, Kahn CR, and Verdin E. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464: 121-125, 2010.
39. Hirschey MD, Shimazu T, Huang JY, and Verdin E. Acetylation of mitochondrial proteins. Methods Enzymol 457: 137-147, 2009.
40. Hitchler MJ, Oberley LW, and Domann FE. Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells. Free Radic Biol Med 45: 1573-1580, 2008.
41. Huang Y, He T, and Domann FE. Decreased expression of manganese superoxide dismutase in transformed cells is associated with increased cytosine methylation of the SOD2 gene. DNA Cell Biol 18: 643-652, 1999.
42. Jain S, Santa-Maria CA, and Gradishar WJ. The role of ovarian suppression in premenopausal women with hormone receptor-positive early-stage breast cancer. Oncology (Williston Park) 29: 473-478, 481, 2015.
43. Jing E, Emanuelli B, Hirschey MD, Boucher J, Lee KY, Lombard D, Verdin EM, and Kahn CR. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc Natl Acad Sci U S A 108: 14608-14613, 2011.
44. Kaewpila S, Venkataraman S, Buettner GR, and Oberley LW. Manganese superoxide dismutase modulates hypoxiainducible factor-1 alpha induction via superoxide. Cancer Res 68: 2781-2788, 2008.
45. Kattan Z, Minig V, Leroy P, Dauca M, and Becuwe P. Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells. Breast Cancer Res Treat 108: 203-215, 2008.
46. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, Vassilopoulos A, Ozden O, Park SH, Singh KK, Abdulkadir SA, Spitz DR, Deng CX, and Gius D. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17: 41-52, 2010.
47. Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, Ji J, Wang XW, Park SH, Cha YI, Gius D, and Deng CX. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20: 487-499, 2011.
48. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, Cheng T, Kho Y, Xiao H, Xiao L, Grishin NV, White M, Yang XJ, and Zhao Y. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23: 607-618, 2006.
49. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19: 1176-1179, 2000.
50. Li JJ, Oberley LW, St Clair DK, Ridnour LA, and Oberley TD. Phenotypic changes induced in human breast cancer cells by overexpression of manganese-containing superoxide dismutase. Oncogene 10: 1989-2000, 1995.
51. Li M, Chiu JF, Mossman BT, and Fukagawa NK. Downregulation of manganese-superoxide dismutase through phosphorylation of FOXO3a by Akt in explanted vascular smooth muscle cells from old rats. J Biol Chem 281: 40429-40439, 2006.
52. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, Kim J, Yancopoulos G, Valenzuela D, Murphy A, Yang Y, Chen Y, Hirschey MD, Bronson RT, Haigis M, Guarente LP, Farese RV, Jr., Weissman S, Verdin E, and Schwer B. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol 27: 8807-8814, 2007.
53. Longo VD and Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci 31: 89-98, 2010.
54. Lumachi F, Brunello A, Maruzzo M, Basso U, and Basso SM. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem 20: 596-604, 2013.
55. Lumachi F, Santeufemia DA, and Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem 6: 231-239, 2015.
56. Mitri Z, Constantine T, and O'Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012: 743193, 2012.
57. Mokbel K. The evolving role of aromatase inhibitors in breast cancer. Int J Clin Oncol 7: 279-283, 2002.
58. Nie H, Chen G, He J, Zhang F, Li M, Wang Q, Zhou H, Lyu J, and Bai Y. Mitochondrial common deletion is elevated in blood of breast cancer patients mediated by oxidative stress. Mitochondrion 26: 104-112, 2016.
59. Nourazarian AR, Kangari P, and Salmaninejad A. Roles of oxidative stress in the development and progression of breast cancer. Asian Pac J Cancer Prev 15: 4745-4751, 2014.
60. Oberley LW and Buettner GR. Role of superoxide dismutase in cancer: a review. Cancer Res 39: 1141-1149, 1979.
61. Ozden O, Park SH, Wagner BA, Yong Song H, Zhu Y, Vassilopoulos A, Jung B, Buettner GR, and Gius D. SIRT3 deacetylates and increases pyruvate dehydrogenase activity in cancer cells. Free Radic Biol Med 76: 163-172, 2014.
62. Park SH, Zhu Y, Ozden O, Kim HS, Jiang H, Deng CX, Gius D, and Vassilopoulos A. SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis. Transl Cancer Res 1: 15-21, 2012.
63. Perez AA, Balabram D, Rocha RM, da Silva Souza A, and Gobbi H. Co-expression of p16, Ki67 and COX-2 is associated with basal phenotype in high-grade ductal carcinoma in situ of the breast. J Histochem Cytochem 63: 408-416, 2015.
64. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, and Botstein D. Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
65. Qiu X, Brown K, Hirschey MD, Verdin E, and Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 12: 662-667, 2010.
66. Rose G, Dato S, Altomare K, Bellizzi D, Garasto S, Greco V, Passarino G, Feraco E, Mari V, Barbi C, BonaFe M, Franceschi C, Tan Q, Boiko S, Yashin AI, and De Benedictis G. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol 38: 1065-1070, 2003.
67. Santa-Maria CA and Gradishar WJ. Changing treatment paradigms in metastatic breast cancer: lessons learned. JAMA Oncol 1: 528-534, 2015; quiz 549.
68. Sarsour EH, Kalen AL, Xiao Z, Veenstra TD, Chaudhuri L, Venkataraman S, Reigan P, Buettner GR, and Goswami PC. Manganese superoxide dismutase regulates a metabolic switch during the mammalian cell cycle. Cancer Res 72: 3807-3816, 2012.
69. Saunders LR and Verdin E. Cell biology. Stress response and aging. Science 323: 1021-1022, 2009.
70. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, and Steegborn C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol 382: 790-801, 2008.
71. Schumacker PT. SIRT3 controls cancer metabolic reprogramming by regulating ROS and HIF. Cancer Cell 19: 299-300, 2011.
72. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, and Verdin E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci U S A 103: 10224-10229, 2006.
73. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, and Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241, 2012.
74. Sipe HJ, Jr., Jordan SJ, Hanna PM, and Mason RP. The metabolism of 17 beta-estradiol by lactoperoxidase: a possible source of oxidative stress in breast cancer. Carcinogenesis 15: 2637-2643, 1994.
75. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, Tanokura M, Denu JM, and Prolla TA. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 143: 802-812, 2010.
76. Spitz DR, Azzam EI, Li JJ, and Gius D. Metabolic oxidation/ reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev 23: 311-322, 2004.
77. Spitz DR and Li GC. Heat-induced cytotoxicity in H2O2-resistant Chinese hamster fibroblasts. J Cell Physiol 142: 255-260, 1990.
78. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill S, Hayes McDonald W, Olivier AK, Spitz DR, and Gius D. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 40: 893-904, 2010.
79. Tao R, Vassilopoulos A, Parisiadou L, Yan Y, and Gius D. Regulation of MnSOD enzymatic activity by Sirt3 connects the mitochondrial acetylome signaling networks to aging and carcinogenesis. Antioxid Redox Signal 20: 1646-1654, 2014.
80. Van Remmen H, Ikeno Y, Hamilton M, Pahlavani M, Wolf N, Thorpe SR, Alderson NL, Baynes JW, Epstein CJ, Huang TT, Nelson J, Strong R, and Richardson A. Lifelong reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol Genomics 16: 29-37, 2003.
81. Vassilopoulos A, Pennington JD, Andresson T, Rees DM, Bosley AD, Fearnley IM, Ham A, Flynn CR, Hill S, Rose KL, Kim HS, Deng CX, Walker JE, and Gius D. SIRT3 deacetylates ATP synthase F1 complex proteins in response to nutrient-and exercise-induced stress. Antioxid Redox Signal 21: 551-564, 2014.
82. Venkataraman S, Jiang X, Weydert C, Zhang Y, Zhang HJ, Goswami PC, Ritchie JM, Oberley LW, and Buettner GR. Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells. Oncogene 24: 77-89, 2005.
83. Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa MC, Ramirez-Tortosa CL, Granados-Principal S, Lorente JA, and Quiles JL. Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies. Crit Rev Oncol Hematol 80: 347-368, 2011.
84. Verdin E, Hirschey MD, Finley LW, and Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci 35: 669-675, 2010.
85. Wang M, Kirk JS, Venkataraman S, Domann FE, Zhang HJ, Schafer FQ, Flanagan SW, Weydert CJ, Spitz DR, Buettner GR, and Oberley LW. Manganese superoxide dismutase suppresses hypoxic induction of hypoxiainducible factor-1alpha and vascular endothelial growth factor. Oncogene 24: 8154-8166, 2005.
86. Warburg O. On the origin of cancer cells. Science 123: 309-314, 1956.
87. Weyemi U, Parekh PR, Redon CE, and Bonner WM. SOD2 deficiency promotes aging phenotypes in mouse skin. Aging (Albany NY) 4: 116-118, 2012.
88. Zhang Y, Zhang HM, Shi Y, Lustgarten M, Li Y, Qi W, Zhang BX, and Van Remmen H. Loss of manganese superoxide dismutase leads to abnormal growth and signal transduction in mouse embryonic fibroblasts. Free Radic Biol Med 49: 1255-1262, 2010.
89. Zhu Y, Park SH, Ozden O, Kim HS, Jiang H, Vassilopoulos A, Spitz DR, and Gius D. Exploring the electrostatic repulsion model in the role of Sirt3 in directing MnSOD acetylation status and enzymatic activity. Free Radic Biol Med 53: 828-833, 2012.
90. Zhu Y, Yan Y, Principe DR, Zou X, Vassilopoulos A, and Gius D. SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis. Cancer Metab 2: 15, 2014.